Opsona appoints CFO and strengthens management team
New CFO & Senior Director of Business Development appointed to Management Team
- Dr Jeremy Skillington, Relocates from San Francisco to Dublin to take up Business Development Role
- David Hurley, Second Key Appointment in Recent Weeks as the Company Advances Clinical Trials Targeting Autoimmune and Inflammatory Diseases
- Following Successful Fundraisings of €21.3 million in 2009, Opsona Expands Team
Dublin, Ireland, 20 November 2009
Opsona Therapeutics, a biotechnology company focused on novel therapeutic and preventative approaches to autoimmune and inflammatorydiseases, announced that it has appointed Dr. Jeremy Skillington as the company's Senior Director of Business Development. The company also announced the appointment of Mr. David Hurley to the role of Chief Financial Officer. Both appointments follow one of the most successful fundraisings in the sector in 2009, proceeds from which will also support the company as it moves its key compound into the clinic.
Commenting on the appointment of new senior executives to the Opsona Therapeutics team, Mark Heffernan, Chief Executive Officer said, 'We are delighted to have seasoned executives like David and Jeremy on board as we enter our next phase of growth. We expect their complementary skills sets and experience to assist Opsona in driving its corporate development goals over the coming years."
Dr. Jeremy Skilington
Dr Skillington has returned to Ireland to take up the role following 11 years in the US where for the last six years he held a senior business development position in Genentech Inc. in San Francisco with particular focus on transactions in the immunology area.
Prior to this Dr Skillington completed his PhD at National University of Ireland (Galway) and his post doctoral research with the University of California, San Francisco.
Mr. David Hurley
David comes to Opsona following previous experience in the biotechnology sector with Elan Pharmaceuticals. He initially held tax and business planning accountability positions with the company, following which he held the position of CFO in the USA from 1996 through to 2004.
For further information please contact:
For media queries please contact:
Tel + 353 1 6633602